drugset / Trial / NCT00454194

Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT00454194 ↗

RandomizedParallel-groupOpen-labelTreatment

Summary

RATIONALE: Pemetrexed disodium and sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Sorafenib may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving pemetrexed disodium together with sorafenib may kill more tumor cells. PURPOSE: This randomized phase II trial is studying pemetrexed disodium and sorafenib to see how well they work compared with pemetrexed disodium alone as second-line therapy in treating patients with stage IIIB or stage IV non-small cell lung cancer.

Timeline

Start
2007-09
Primary completion
2010-07
Completion
2013-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Pemetrexed Small molecule — Intravenous
Subject Sorafenib Small molecule — Oral

Indications